CIS Pharma Competitors and Similar CompaniesClear all

CIS Pharma's competitors and similar companies include ASKA Pharmaceutical, Dong-A ST, Phapros and Kaken Pharmaceutical.

	CIS Pharma CIS Pharma is a pharmaceutical research and development company specializing in drug delivery.	ASKA Pharmaceutical ASKA Pharmaceutical (あすか製薬株式会社) is a company that develops, manufactures, and sells pharmaceutical products.	Dong-A ST Dong-A ST is a healthcare company that specializes in the development of ethical drugs and medical devices.	Phapros PT Phapros Tbk is engaged in pharmaceutical manufacturing.	Kaken Pharmaceutical Kaken Pharmaceutical is a company providing pharmaceuticals and medical devices in the orthopedics and dermatology fields.
Founding Date	Founding Date 1952	Founding Date 1920	Founding Date 1932	Founding Date 1954	Founding Date 1948
Type	Type Private	Type Subsidiary	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech drug development life sciences medical devices medtech pharma	Tags Healthcare drug development pharma veterinary	Tags Healthcare biotech drug development medical devices medtech pharma	Tags Healthcare drug development medical devices medtech pharma	Tags Healthcare biotech drug development medical devices pharma
Locations	Locations Bubendorf, CH HQ	Locations Tokyo, JP HQ Chiba, JP Fujisawa, JP Fukuoka, JP Hiroshima, JP Iwaki, JP Kanazawa, JP see more	Locations HQ	Locations HQ	Locations Bunkyo City, JP HQ
Employees	Employees 10	Employees 635	Employees 1,533	Employees N/A	Employees 1,135
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) ¥52.5b (FY, 2020)	Revenue (est.) ₩808.8b (FY, 2025)	Revenue (est.) N/A	Revenue (est.) ¥94b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods ¥24.9b (FY, 2020)	Cost of goods ₩456.1b (FY, 2025)	Cost of goods N/A	Cost of goods ¥33.2b (FY, 2025)
Gross profit	Gross profit N/A	Gross profit ¥27.7b (FY, 2020)	Gross profit ₩356.5b (FY, 2025)	Gross profit N/A	Gross profit ¥60.8b (FY, 2025)
Net income	Net income N/A	Net income ¥649m (FY, 2020)	Net income (₩37.6b) (FY, 2025)	Net income N/A	Net income ¥13.9b (FY, 2025)